RecruitingPhase 3NCT06512584

Efficacy and Safety of PJ009 in Patients With Short Bowel Syndrome Requiring Parenteral Nutrition

Studying Short bowel syndrome

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Chongqing Peg-Bio Biopharm Co., Ltd.
Principal Investigator: Huanlong Qin
Shanghai 10th People's Hospital
Intervention: PJ009(drug)
Enrollment: 72 enrolled
Eligibility: 14 years · All sexes
Timeline: 2024 – 2026

Study locations (8)

Beijing Tsinghua Changgung Hospital, Beijing, Beijing Municipality, China
Chongqing General Hospital, Chongqing, Chongqing Municipality, China
The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
The Third Xiangya Hospital of Central South University, Changsha, Hu'Nan, China
General Hospital of Eastern Theater Command, Nanjing, Jiangsu, China
The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
Shanghai Tenth People's Hospital, Shanghai, Shanghai Municipality, China
The First Affiliated Hospital of Xi'an Jiaotong University, Xi’an, Shanxi, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06512584 on ClinicalTrials.gov

Other trials for Short bowel syndrome

Additional recruiting or active studies for the same condition.

See all trials for Short bowel syndrome →

← Back to all trials